Norges Bank
FDMT icon

Norges Bank’s 4D Molecular Therapeutics FDMT Stock Holding History

Norges Bank’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54,219
Closed -$201K – 554
2025
Q2 		$201K Buy
+54,219
New +$191K ﹤0.01% 1692
2025
Q1 		– Sell
-500,823
Closed -$2.79M – 1780
2024
Q4 		$2.79M Sell
500,823
-23,888
-5% -$187K ﹤0.01% 1644
2024
Q3 		$5.67M Buy
+524,711
New +$8.71M ﹤0.01% 1497
2024
Q2 		– Sell
-54,219
Closed -$1.73M – 1953
2024
Q1 		$1.73M Buy
+54,219
New +$1.38M ﹤0.01% 1749
2023
Q2 		– Sell
-294,000
Closed -$5.05M – 2047
2023
Q1 		$5.05M Hold
294,000
– – ﹤0.01% 1752
2022
Q4 		$6.53M Buy
+294,000
New +$4.54M ﹤0.01% 1704
2021
Q1 		– Sell
-5,000
Closed -$207K – 2154
2020
Q4 		$207K Buy
+5,000
New +$206K ﹤0.01% 2104

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Norges Bank's FDMT Position: Q3 2025 in Review

Norges Bank sold out of 4D Molecular Therapeutics (FDMT) in Q3 2025, closing a stake of 54,219 shares — an estimated $201K sold.

Norges Bank first reported a position in FDMT in Q4 2020 and held it in 7 quarters. The position peaked at $6.53M in Q4 2022. 134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

  • Norges Bank reported no remaining 4D Molecular Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 54,219 4D Molecular Therapeutics shares in Q3 2025, an estimated $201K.
  • Norges Bank first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 7 quarters.
  • Norges Bank's 4D Molecular Therapeutics position peaked at $6.53M in Q4 2022.
  • 134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.